Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific... – Synthetic or structurally-modified peptidoglycan or...
Reexamination Certificate
1998-02-11
2001-12-04
Stucker, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
Synthetic or structurally-modified peptidoglycan or...
C424S184100, C424S185100, C424S186100, C424S190100, C424S093710, C530S395000
Reexamination Certificate
active
06326009
ABSTRACT:
BACKGROUND OF THE INVENTION
Vertebrates have two basic immune responses: humoral or cellular. Humoral immunity is provided by the special class of cells produced by B lymphocytes. These cells produce antibodies which circulate in the blood and lymphatic fluid. On the other hand, cell mediated immunity is provided by the T cells of the lymphatic system.
The cellular immune response is particularly effective against fungi, parasites, intracellular viral infections, cancer cells and foreign matter, whereas the humoral response primarily defends against the extracellular phases of bacterial and viral infections.
Containment of antigen at its point of entry is accomplished by walling off the area by local inflammation. Acute inflammation is characterized by the influx of plasma proteins and polymorphonuclear leukocytes. Chronic inflammation is characterized by the infiltration of T-lymphocytes and macrophages. When acute (antibody induced) and chronic (T-cell induced) inflammations occur in the skin, they are called immediate and delayed type hypersensitivity reactions respectively. ITH peaks at 24 hours, and subsides in 48 hours DTH appears in 24-48 hours and peaks at 48-72 hours. The subset of T cells involved in DTH reactions are called here DTH-Effector cells.
Epiglycanin (epi) is the major cell surface glycoprotein produced by the mammary adenocarcinoma transplantable cell line TA3Ha. Friberg, Jr., J.N.C.I., 48:1463 (1972); Codington, et al., Canc. Res., 43:4373 (1983). The TA3Ha carcinoma cells are covered by a mucin-like glycocalix composed mainly of epiglycanin. Codington, et al., J.N.C.I., 60:811 (1978); Miller, et al., J.N.C.I., 68:981 (1982). Epi is mainly carbohydrate in composition, and expresses multiple T and Tn determinants. T and Tn are general carcinoma autoantigens. Springer, Science, 224:1198 (1984).
Synthetic T and Tn antigens have been prepared, and used in DTH diagnostics. Lemieux, Ep Appl. 44,188. However, their therapeutic or prophylactic use has not been disclosed.
Bretscher, Eur. J. Immunol., 9:311-316 (1979) cultured DTH-Effector cells in vitro and injected them with the sensitizing antigen (burro erythrocytes) into the foot pads of mice. We have used cancer-associated, well characterized carbohydrate antigens to sensitize effector cells and have taught a therapeutic use for them.
It is known that tumors may be treated with a mixture of IL-2 and IL-2-activated killer cells. See Fortune, 16-21 (Nov. 25, 1985), reporting on the work of Steven Rosenberg. The IL-2 induces a general immune response. It thus places a heavy burden on the immune system, diverting resources from the desired cellular response. High, possibly toxic levels of IL-2 are required to induce a cellular response. At these levels, it may unintentionally induce an autoimmune response. Our procedure induces a response which is specific, because the cells recognize a cancer-associated carbohydrate marker only a low level of our inducer is required to stimulate the cellular immune system.
SUMMARY OF THE INVENTION
We have found that the cell-mediated immune response to cancer cells is enhanced by parenteral administration of natural and synthetic cancer-associated carbohydrate antigens or by parenteral administration of DTH effector cells primed by such antigens. This enhancement is likely to be advantageous for both therapy and prophylaxis when the body's primary defense against a challenge is a cellular immune response, e.g., against tumors. The use of other specific carbohydrate antigens, including polysaccharides, glycolipids and glycoproteins, may be useful in protecting a subject against other threats controlled by T cells. It is known that parasites, viruses, bacteria and fungi bear surface carbohydrate determinants.
While we do not favor the use of lymphokines (e.g., IL-2) alone to induce a general cellular immune response, lymphokines may be used in conjunction with the specific antigens or primed DTH-Effector cells of this invention to enhance the specific CMI response.
REFERENCES:
patent: 4180627 (1979-12-01), Klesius et al.
patent: 4690915 (1987-09-01), Rosenberg
patent: 4971795 (1990-11-01), Longenecker et al.
patent: 2106935 (1983-04-01), None
Henningsson, et al., Induction of Immunity to a Mammary Adenocarcinoma using Purified shed Cancer Antigen and Synthetic Carbohydrates, Journal of Leukocyte Biology, vol. 38, abstract No. 70, Jul. 1985.
Henningsson, et al., Induction of Immunity to a Mammary Adenocarcinoma using Purified Shed Cancer Antigen and Synthetic Carbohydrate Tumor Associated Antigens, 5th Ann. Heritage Med. Res. Days, p. 52, Abstract No. 130, Nov. 21, and 22, 1985.
Henningsson, et al., Induction of Immunity to a Mammary Adenocarcinoma using Purified Shed Cancer Antigen and Snythetic carbohydrates, 6th Int. Congress of Immunology, Jul., 1986.
Codington, JF et al., “Further Studies on the Relationship Between Large Glycoprotein Molecules and Allotransplantability in the TA3 Tumor of the Mouse: Studies on Segregating TA3-Ha Hybrids”,J. Natl. Cancer Inst.6(4): 811-818 (Apr. 1978).
Codington, JF et al., “Cell Surface Characteristics of an Allotransplantable TA3 Ascites Subline Resulting from a Process of Immunoselection”,Cancer Research43:4373-4381 (Sep. 1983).
Friberg, S et al., “Comparison of an Immunoresistant and an Immunosusceptible Ascites Subline From Muring Tumor TA3. I. Transplantability, Morphology, and Some Physicochemical Characteristics”,J. Nat. Cancer Inst.48: 1463-1476 (1972).
Bretscher, PA, “In vitro induction of delayed-type hypersensitivity”,Eur. J. Immunol.9:311-316 (1979).
Klein, ed., Immunology: The Science of Self-Nonself Discrimination 465 (1982).
Goldstein, et al., J. Exp. Med., 162:1381 (1985).
Myrvik, et al., Fundamentals of Immunology 135-41 (1984).
Moreno, “Carbohydrates as Immunogens and Tolerogens: Antibody versus Cell-Mediated Immune Responses”, inTowards Better Carbohydrates Vaccines,Chapter 19 (1987) at pp. 263, 267.
Springer, et al, 1984, “T and Tn General . . . ” Science 224: 1198-1206.*
Bianchi, et al, 1981, “Clones of T cells mediate antigen-specific . . . ” Nature 290 62-63.*
Leung, et al, 1980, “Specificity, Ly phenotype and H-2 . . . ” J. Exp. Med 151:815-826.*
Greene, et al, 1984, “Delayed Hypersensitivity” In Fundamental Immunology, W.E. Paul Ed p. 685-696.*
Ertl, Cell Immunol, 62, 38-49, (1981).*
Benjamini et al, Chapter 15 in Basic and Clinical Immunology, Stites et al eds, 1984 (5thEdition), Los Altos, CA.*
Lefford,Immunology,41, 635, (1980).*
Chemical Abstracts, 78, 27836Z (for Cooper, Scand. J. Immunol., 1(3), 237-45).*
Havelle et al, J. Immunol, 137(5), 1448-54, 1986.*
Miller, et al. 1982 “Further Studies on the relationship between . . . ” J. N. C. I. 68(6): 981-985.
Henningsson Carina
Longenecker B. Michael
Biomira, Inc.
Cooper Iver P.
Stucker Jeffrey
LandOfFree
Enhancement of the cellular immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhancement of the cellular immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancement of the cellular immune response will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2561923